$BRKR

Munch Mark sold $120K of BRKR

Munch Mark (EXEC VP&PRES BRUKER NANO INC.) sold 2,000 shares of BRUKER CORP (BRKR) at $60.25 ($0.12M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Munch Mark
Published Jul 16, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
medium confidence
Mentioned
$BRKR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and confirms the sale was executed under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article provides only one transaction and does not indicate whether there were offsetting buys, changes in total insider holdings beyond the post-sale figure, or broader company news.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-16 for a sale executed on 2026-07-15.

Background

This is an SEC Form 4 insider transaction disclosure for Bruker Corp, reported by an executive officer associated with Bruker Nano.

Company-level read

Ticker impact

$BRKRNeutralMedium confidence
Context

Bruker Corp insider Form 4 shows exec VP and Pres Bruker Nano sold 2,000 shares on 2026-07-15 at $60.25 via a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying new operational or financial information.

Market effects

No clear sector read-through from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Insider selling can still reflect private caution, even if executed under 10b5-1, especially if multiple recent sales cluster.

Key entities

  • BRUKER CORP

    Company whose insider transaction is disclosed on Form 4.

  • Munch Mark

    Executive VP and Pres, Bruker Nano, who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that governs the timing of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

J.P. Morgan Downgrades Bruker Corporation (BRKR) to Neutral Amid

J.P. Morgan downgraded Bruker Corporation (BRKR) to Neutral with a $70 price target, citing concerns about its Academia & Government segment and uncertain revenue growth. Bruker's P/S ratio is 2.45x, below its historical median and industry average. The company has a GF Score of 84/100, with strengths in valuation and momentum, but faces insider selling and mixed institutional interest.

$BRKRMed

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

J.P. Morgan downgraded Bruker (BRKR) to Neutral and Sotera Health (SHC) to Underweight, citing uncertainty in their respective markets. Analyst Casey Woodring maintained a $70 price target for Bruker but expressed concerns about its exposure to lagging segments. For Sotera, Woodring lowered the price target to $17 from $18, citing underperformance tied to its medtech client base.

$BRKRMed

BRKR Stock Slides As Fusion Deal Collides With UBS Reality Check

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

$BRKRMed

BRKR Stock Pulls Back As Fusion Bet And UBS Target Collide

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.